GlassScriptPhysician profile
Monique Rosser
NPI 1730786047
$1,770.04
in general payments reported to CMS, 2019-2025
23 companies · $504 in 2025
The $504 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $20.50 · 2022: $193 · 2023: $603 · 2024: $449 · 2025: $504.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,557.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,557.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $340.89 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $315.85 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Boston Scientific Corporation | $227.30 | 2023-2025 | Spaceoar Vue System - 10ml, Rezum Generator, General - Pain Management |
| Abbvie INC. | $144.94 | 2022-2025 | |
| Astellas Pharma US INC | $96.74 | 2023-2025 | Veozah |
| Shield Therapeutics INC | $84.45 | 2024-2025 | |
| Exact Sciences Corporation | $70.81 | 2023-2025 | Cologuard Collection Kit |
| Pfizer INC. | $68.95 | 2024-2025 | |
| Corium, LLC | $45.13 | 2025 | Azstarys |
| Tris Pharma INC | $44.77 | 2024-2025 | Dyanavel Xr |
| Merck Sharp & Dohme LLC | $44.51 | 2023-2024 | Belsomra, Gardasil, Gardasil 9 |
| Astrazeneca Pharmaceuticals LP | $40.96 | 2022-2024 | Farxiga |
| Neos Therapeutics, LP | $39.96 | 2023 | Adzenys Xr-Odt |
| Idorsia Pharmaceuticals US INC | $32.49 | 2023-2025 | Quviviq, Quviviq |
| Glaxosmithkline, LLC. | $30.65 | 2025 | Bexsero, Arexvy, Shingrix |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $24.25 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $21.19 | 2023 | Trintellix |
| Olympus America INC. | $20.50 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $20.28 | 2023 | Rexulti |
| Supernus Pharmaceuticals, INC. | $16.19 | 2025 | Qelbree |
| Linus Health, INC. | $13.89 | 2023 | |
| Amgen INC. | $12.90 | 2023 | Otezla, Repatha |
| Medtronic, INC. | $12.44 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Monique Rosser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.